Elizabeth Batterton, MD
Sports Medicine · Phoenix, AZNPI 1639435266
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,144 of the $37,778 with a category attached, or 77.1%. Pacira Therapeutics, Inc. accounts for 83.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $22,346 and has fallen 86.7% since, to $2,966 in 2025.
Across 184 payments — averaging $205.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$32K
- Pylant Medical$2K
- Arthrex$1K
- Hydrocision, Inc.$940
- Impactortho, Inc.$876
- Bioventus LLC$327
- plus $1K from 9 others
What the payments were for
- Speaking & faculty fees$29,14477%
- Travel & lodging$3,0078%
- Food & beverage$4,10911%
- Education$1,5194%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 85 | $31,655 |
| Pylant Medical | 3 | $1,525 |
| Arthrex | 9 | $1,338 |
| Hydrocision, Inc. | 11 | $940 |
| Impactortho, Inc. | 7 | $876 |
| Bioventus LLC | 8 | $327 |
| Ferring Pharmaceuticals Inc. | 24 | $298 |
| Nevro Corp. | 2 | $200 |
| Amgen | 11 | $163 |
| DJO, LLC | 7 | $151 |
| Johnson & Johnson | 5 | $95 |
| Pacira Pharmaceuticals Incorporated | 5 | $87 |
| Fidia Pharma USA Inc. | 5 | $87 |
| Smith+Nephew | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,778 in reported general payments places this provider in the 85th percentile of 152 sports medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 26 | $223 |
| Meloxicam | 24 | $45 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Phoenix
- Anup ShahPhoenix$1.3M
- Rafael Buerba SillerPhoenix$63K
- Kade McQuiveyPhoenix$61K
- Tony NguyenPhoenix$38K
- Trevor StaubPhoenix$25K
- Keith JarboPhoenix$16K
- Laura Vogel AbernathiePhoenix$12K
- Elliot MendelsohnPhoenix$9K
- Matthew SteelePhoenix$9K
- Alexander HofferPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.